News

Akeso's Ivonescimab Sets New Standards in NSCLC Treatment

Akeso's Ivonescimab Sets New Standards in NSCLC Treatment

Akeso's Groundbreaking Clinical Trial Results

Akeso, Inc. (9926.HK) is thrilled to share significant breakthroughs from its Phase III clinical study of ivonescimab, a cutting-edge PD-1/VEGF bispecific antibody designed to treat non-small cell lung cancer (NSCLC). The study, known as HARMONi-2/AK112-303, has garnered attention following its publication in The Lancet, one of the most prestigious medical journals worldwide.

Impact of The Lancet Publication

The publication of the HARMONi-2 study in The Lancet underscores the academic community's recognition of ivonescimab's potential to transform cancer treatments. Previously, this innovative treatment has been highlighted in prominent journals, showcasing its encouraging efficacy across various types of cancer.

Presentation at World Conference on Lung Cancer

A remarkable presentation at the World Conference on Lung Cancer reiterated the strength of the study results. The principal investigator, Professor Zhou Caicun, an esteemed oncologist and President-Elect of IASLC, emphasized the promising outcomes of the trial. The results indicated that ivonescimab significantly enhances progression-free survival compared to pembrolizumab in patients with locally advanced or metastatic PD-L1 positive NSCLC.

Significant Findings from the HARMONi-2 Study

The HARMONi-2 trial provided crucial insights showing that ivonescimab reduced the risk of disease progression by 49%, a remarkable achievement in the field of oncology. It demonstrated consistent efficacy across various patient demographics, thereby reinforcing its applicability in diverse clinical settings. This marked a historic moment as ivonescimab became the first treatment of its kind to show such a degree of effectiveness in a randomized controlled trial against pembrolizumab.

Review and Approval Status

With its promising results, the supplemental New Drug Application for ivonescimab as a primary treatment for PD-L1 positive NSCLC is currently undergoing review, receiving priority status in China. Additionally, ivonescimab has already been incorporated into the China National Reimbursement Drug List in combination with chemotherapy, facilitating broader access for patients.

Strategic Development Plans for Ivonescimab

Akeso remains dedicated to expanding ivonescimab's role in cancer immunotherapy through a comprehensive development plan. This strategy aims to elevate standards of care globally by continuing to validate the efficacy and safety of ivonescimab through ongoing multicenter clinical trials.

Current and Upcoming Clinical Trials

As part of its initiatives, Akeso is collaborating with Summit Therapeutics on three international Phase III clinical trials:

  • The HARMONi study evaluates ivonescimab combined with chemotherapy for patients who have progressed following third-generation EGFR-TKI treatment. This trial has completed patient enrollment and achieved Fast Track Designation from the FDA.
  • The HARMONi-3 study focuses on combining ivonescimab with chemotherapy as a first-line treatment for both squamous and non-squamous NSCLC.
  • The HARMONi-7 study investigates ivonescimab as a monotherapy for high-expressing PD-L1 NSCLC patients.

In addition to these trials, several more are underway in China:

  • Testing ivonescimab with chemotherapy in first-line squamous NSCLC patients.
  • Evaluating ivonescimab in biliary tract cancer treatments.
  • Investigating its effectiveness in combination with AK117 for head and neck squamous cell carcinoma.
  • Exploring treatment options for triple-negative breast cancer.

Conclusion

Akeso's commitment to advancing cancer therapies through innovative approaches is evident in its continuous efforts to integrate ivonescimab into key treatment standards. The promising results from clinical trials highlight its potential to change how non-small cell lung cancer is treated, offering new hope to patients and the medical community alike.

Frequently Asked Questions

What is ivonescimab?

Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody developed by Akeso, Inc. to treat non-small cell lung cancer.

What were the results of the Phase III clinical trial?

The HARMONi-2 trial demonstrated that ivonescimab significantly improved progression-free survival compared to pembrolizumab.

What does the publication in The Lancet mean?

Being published in The Lancet signifies recognition of ivonescimab’s clinical potential by the international medical community.

Which other cancers besides NSCLC is ivonescimab being studied for?

Ivonescimab is also being evaluated for biliary tract cancer, head and neck squamous cell carcinoma, and triple-negative breast cancer.

What trials are currently ongoing?

Several clinical trials are underway, including studies comparing ivonescimab with chemotherapy for various cancer types.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

COP31 Puts China’s Weather-to-Energy Model on View

Updated Category News Views 76

Storm maps are becoming operating manuals, and that is the hard reality behind a November 13 COP31 event in Antalya, Türkiye. The session, “From Early Warning to Energy Action: Pathways for Global Climate Diplomacy and Cooperation,” put China’s effort to tie meteorological intelligence to energy-system decisions under an international spotlight. This is not...

Continue Reading
Teachstone’s Bronze Award Puts Classroom Quality in Focus

Updated Category News Views 0

Small Classroom Moments Finally Get Their Due A child’s hesitant question can disappear in the noise of a busy classroom, which is precisely why Teachstone’s latest recognition deserves more than the usual polite golf clap. The Charlottesville-based Certified B Corporation received a Bronze Anthem Award for its “From Measurement to Momentum” initiative, in the...

Continue Reading
Sogroya Approval Broadens Novo's Pediatric Growth Franchise

Updated Category News Views 14

Seven fewer injections every week is the real headline behind Novo Nordisk's latest FDA clearance, not some flashy efficacy leap. On November 20, 2026, the company said Sogroya, its once-weekly long-acting growth hormone, won approval for children aged 2.5 and older with growth failure associated with Turner syndrome. That matters because treatment can stretch over years,...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 18

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 84

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Pinnacol’s Community Work Earns Denver Chamber Recognition

Updated Category News Views 27

A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...

Continue Reading
CASEKOO's Montana Story Makes Brand Purpose Personal

Updated Category News Views 19

A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 79

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 36

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading
Trip.Best Expands Global Travel Discovery Footprint

Updated Category News Views 123

Sydney just became the map pin for a fairly serious travel-content land grab. Trip.Best, Trip.com Group's ranking brand, has rolled out its 2027 Annual Rankings with coverage of all seven continents for the first time. This is not an earnings release, and nobody should pretend a hotel list magically turns into revenue by lunchtime. Still, the jump from 85 to 98 annual...

Continue Reading

Top 5 Most Recently Viewed Articles

3D Marketing & Services, LLC Enhances Global Presence with RADIUM

Updated Category News Views 149

3D Marketing & Services, LLC Enhances Global Presence with RADIUM LIMITED In an exciting development, 3D Marketing & Services, LLC, a dynamic digital marketing and media distribution agency, proudly announces a transformative partnership with RADIUM LIMITED. This collaboration marks a significant growth milestone for 3D Marketing, emphasizing their commitment to deliver...

Continue Reading
Aerospace Riveting Equipment Market Expected to Surge

Updated Category News Views 88

Aerospace Riveting Equipment Market Expected to Surge The aerospace riveting equipment market is on an impressive growth trajectory. Estimates indicate that this sector, valued at USD 109 million in 2023, could reach as high as USD 134 million by 2028, expanding at a compound annual growth rate (CAGR) of 4.3% during this period. Numerous factors contribute to robust...

Continue Reading
Kinetic Seas CEO Edward Honour Reflects on Last Year's Growth

Updated Category News Views 309

Kinetic Seas CEO Edward Honour Reflects on Last Year's Growth Kinetic Seas (OTC: KSEZ) has charted a remarkable journey since we took operational control just over a year ago. I am Edward Honour, your CEO and Chairman of the Board. In this letter, I will share the inspiring story of our company's evolution and the challenges we overcame along the way. Our Vision and...

Continue Reading
Investigation into The Greenbrier Companies, Inc. by Investors

Updated Category News Views 351

Investigation Overview of The Greenbrier Companies Pomerantz LLP is currently conducting an investigation on behalf of the investors of The Greenbrier Companies, Inc. (NYSE: GBX). This inquiry seeks to uncover any possible securities fraud or unlawful practices involving the company's executives. Company Financial Performance The investigation follows Greenbrier's...

Continue Reading
Exploring Charles Schwab's Remarkable Growth Over Two Decades

Updated Category News Views 169

The Growth of Charles Schwab Over Twenty Years Charles Schwab (NYSE: SCHW) has shown remarkable performance over the last two decades, consistently outperforming the market. With an annualized growth rate that eclipses broader market returns by 1.21%, investors have witnessed an impressive average annual return of 10.08%. Investment Value After 20 Years Imagine if an...

Continue Reading